Cd209a

What is CD209A protein?

CD209A gene (CD209a antigen) is a protein coding gene which is considered to be a homologue of the human DC-SIGN (hDC-SIGN). CD209a, also known as SIGNR5, is a protein found in mice, and CD209a is similar to hDC-SIGN in expression pattern and genomic localization in mice, so it is used as a model to study the function of hDC-SIGN. The expression of CD209a in the body is concentrated on myeloid cells in the skin and spleen, where the pathogen is most likely to be encountered. The CD209A protein is consisted of 238 amino acids and CD209A molecular weight is approximately 27.1 kDa.

What is the function of CD209A protein?

CD209A, also known as DC-SIGN, is a C-type lectin receptor expressed on dendritic cells and certain macrophages. It is mainly involved in the recognition of pathogens, and promotes the phagocytosis and processing of pathogens through its carbohydrate recognition domain binding to the sugar chains on the surface of pathogens. In addition, CD209A plays a key role in antigen presentation, mediating the endoannexation of antigens through MHC Class II molecules to present antigens to T cells and activate adaptive immune responses. CD209A is also involved in intercellular adhesion, contributing to the interaction between immune cells. In terms of immune regulation, CD209A affects the balance of inflammatory response and immune tolerance. In vaccine development, strategies targeting CD209A can effectively activate adaptive immune responses and induce specific T cell and antibody responses.

Fig1. CD209a-dependent induction of pathogenic Th17 cell response. (Holly E Ponichtera, 2015)

CD209A related signaling pathway

The CD209A protein, also known as DC-SIGN, participates in a signaling pathway primarily through its function as a C-type lectin receptor. It recognizes and binds to sugar chains on the surface of a variety of pathogens, activating downstream signaling pathways. In mice, CD209A is especially expressed on dendritic cells and macrophages, and by binding to pathogens, it can promote phagocytosis and processing of pathogens, while activating related signaling pathways, such as MAPK signaling pathway, and thereby inducing the production of pro-inflammatory cytokines, such as IL-1β and IL-23. These cytokines are essential for initiating and regulating the immune response. In addition, CD209A was able to quickly reappear on the cell surface after mediating endocytosis of the antigen, suggesting that it also plays an important role in antigen presentation. In immune cells such as dendritic cells, the expression of CD209A is critical for the pathogen-induced production of IL-1β and IL-23 and the subsequent differentiation of Th17 cells.

CD209A related diseases

CD209A is a C-type lectin receptor expressed on dendritic cells and certain macrophages, which plays a key role in the occurrence and development of a variety of diseases. It is involved in the recognition and presentation of a variety of pathogens, including HIV, Ebola virus, Mycobacterium tuberculosis, Candida albicans, schistosoma and Helicobacter pylori, helping to activate the host immune response. Furthermore, CD209A expression in schistosomiasis is associated with a Th17 cell response, which may lead to severe immunopathological changes. In a sepsis model, CD209A improved survival in mice by activating macrophages. CD209A may also be associated with tumor development and prognosis and may serve as a potential target for immunotherapy. It also plays a role in the regulation of autoimmune diseases and immune tolerance. Overall, CD209A plays a multifaceted role in infectious diseases, immune-mediated pathological processes, and possibly tumor immunotherapy.

Bioapplications of CD209A

In the diagnosis and treatment of infectious diseases, CD209A has potential application value in the diagnosis and treatment of infectious diseases due to its ability to recognize multiple pathogens. In addition, CD209A is also a key target in vaccine development, and by coupling antigens to CD209A, it can effectively deliver antigens to dendritic cells, thereby activating adaptive immune responses and enhancing vaccine effectiveness. In terms of disease diagnosis, the expression level of CD209A may serve as a biomarker in some diseases, such as colon cancer, and contribute to the early diagnosis and prognosis assessment of the disease. In terms of immune regulation, CD209A plays a role in regulating the immune response and may affect the balance of inflammatory response and immune tolerance. In addition, CD209A also plays a role in the study of immune escape mechanism, for example, in immune checkpoint therapy, CD209A may be involved in regulating the sialylation modification of antibodies and affecting the function of antibodies.